No evidence that GATA3 rs570613 SNP modifies breast cancer risk

AUTHOR GROUP; K. Aittomaki; SV Hodgson; FB Hogervorst; M.A. Rookus; C. Seynaeve; J.G. Wijnen; M. van Vreeswijk; M.J.L. Ligtenberg; R. van der Luijt; J.J.P. Gille; M.M. Blok; C. Issacs; M.K. Humphreys; L. McGuffog; S. Healey; O.M. Sinilnikova; A.C. Antoniou; D. Easton; G. Chenevix-Trench

doi:https://doi.org/10.1007/s10549-008-0257-1

No evidence that GATA3 rs570613 SNP modifies breast cancer risk

AUTHOR GROUP, K. Aittomaki, SV Hodgson, FB Hogervorst, M.A. Rookus, C. Seynaeve, J.G. Wijnen, M. van Vreeswijk, M.J.L. Ligtenberg, R. van der Luijt, J.J.P. Gille, M.M. Blok, C. Issacs, M.K. Humphreys, L. McGuffog, S. Healey, O.M. Sinilnikova, A.C. Antoniou, D. Easton, G. Chenevix-Trench

Research output: Contribution to journal › Article › Academic › peer-review

8 Citations (Scopus)

Abstract

GATA-binding protein 3 (GATA3) is a transcription factor that is crucial to mammary gland morphogenesis and differentiation of progenitor cells, and has been suggested to have a tumor suppressor function. The rs570613 single nucleotide polymorphism (SNP) in intron 4 of GATA3 was previously found to be associated with a reduction in breast cancer risk in the Cancer Genetic Markers of Susceptibility project and in pooled analysis of two case-control studies from Norway and Poland (P (trend) = 0.004), with some evidence for a stronger association with estrogen receptor (ER) negative tumours [Garcia-Closas M et al. (2007) Cancer Epidemiol Biomarkers Prev 16:2269-2275]. We genotyped GATA3 rs570613 in 6,388 cases and 4,995 controls from the Breast Cancer Association Consortium (BCAC) and 5,617 BRCA1 and BRCA2 carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). We found no association between this SNP and breast cancer risk in BCAC cases overall (OR(per-allele) = 1.00, 95% CI 0.94-1.05), in ER negative BCAC cases (OR(per-allele) = 1.02, 95% CI 0.91-1.13), in BRCA1 mutation carriers RR(per-allele) = 0.99, 95% CI 0.90-1.09) or BRCA2 mutation carriers (RR(per-allele) = 0.93, 95% CI 0.80-1.07). We conclude that there is no evidence that either GATA3 rs570613, or any variant in strong linkage disequilibrium with it, is associated with breast cancer risk in women

Original language	English
Pages (from-to)	371-379
Journal	Breast cancer research and treatment
Volume	117
Issue number	2
DOIs	https://doi.org/10.1007/s10549-008-0257-1
Publication status	Published - 2009

Access to Document

https://doi.org/10.1007/s10549-008-0257-1

https://research.vumc.nl/ws/files/162321/PMC2728174.pdf

Cite this

AUTHOR GROUP, Aittomaki, K., Hodgson, SV., Hogervorst, FB., Rookus, M. A., Seynaeve, C., Wijnen, J. G., van Vreeswijk, M., Ligtenberg, M. J. L., van der Luijt, R., Gille, J. J. P., Blok, M. M., Issacs, C., Humphreys, M. K., McGuffog, L., Healey, S., Sinilnikova, O. M., Antoniou, A. C., Easton, D., & Chenevix-Trench, G. (2009). No evidence that GATA3 rs570613 SNP modifies breast cancer risk. Breast cancer research and treatment, 117(2), 371-379. https://doi.org/10.1007/s10549-008-0257-1

@article{b8d8f0fec6984cb3b697fb4931f57512,

title = "No evidence that GATA3 rs570613 SNP modifies breast cancer risk",

abstract = "GATA-binding protein 3 (GATA3) is a transcription factor that is crucial to mammary gland morphogenesis and differentiation of progenitor cells, and has been suggested to have a tumor suppressor function. The rs570613 single nucleotide polymorphism (SNP) in intron 4 of GATA3 was previously found to be associated with a reduction in breast cancer risk in the Cancer Genetic Markers of Susceptibility project and in pooled analysis of two case-control studies from Norway and Poland (P (trend) = 0.004), with some evidence for a stronger association with estrogen receptor (ER) negative tumours [Garcia-Closas M et al. (2007) Cancer Epidemiol Biomarkers Prev 16:2269-2275]. We genotyped GATA3 rs570613 in 6,388 cases and 4,995 controls from the Breast Cancer Association Consortium (BCAC) and 5,617 BRCA1 and BRCA2 carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). We found no association between this SNP and breast cancer risk in BCAC cases overall (OR(per-allele) = 1.00, 95% CI 0.94-1.05), in ER negative BCAC cases (OR(per-allele) = 1.02, 95% CI 0.91-1.13), in BRCA1 mutation carriers RR(per-allele) = 0.99, 95% CI 0.90-1.09) or BRCA2 mutation carriers (RR(per-allele) = 0.93, 95% CI 0.80-1.07). We conclude that there is no evidence that either GATA3 rs570613, or any variant in strong linkage disequilibrium with it, is associated with breast cancer risk in women",

author = "Johnatty, {Sharon E.} and Couch, {Fergus J.} and Zachary Fredericksen and Robert Tarrell and Spurdle, {Amanda B.} and Jonathan Beesley and Xiaoqing Chen and Daphne Gschwantler-Kaulich and Singer, {Christian F.} and Christine Fuerhauser and Anneliese Fink-Retter and Domchek, {Susan M.} and Nathanson, {Katherine L.} and Pankratz, {Vernon S.} and Lindor, {Noralane M.} and Godwin, {Andrew K.} and Caligo, {Maria A.} and John Hopper and Southey, {Melissa C.} and Giles, {Graham G.} and Christina Justenhoven and Hiltrud Brauch and Ute Hamann and Yon-Dschun Ko and Tuomas Heikkinen and Kirsimari Aaltonen and Kristiina Aittom{\"a}ki and Carl Blomqvist and Heli Nevanlinna and Per Hall and Kamila Czene and Jianjun Liu and Susan Peock and Margaret Cook and Radka Platte and {Gareth Evans}, D. and Fiona Lalloo and Rosalind Eeles and Gabriella Pichert and Diana Eccles and Rosemarie Davidson and Trevor Cole and Jackie Cook and Fiona Douglas and Carol Chu and Shirley Hodgson and Joan Paterson and {van Os}, {Theo A. M.} and {AUTHOR GROUP} and Cora Aalfs and Hanne Meijers-Heijboer and K. Aittomaki and SV Hodgson and FB Hogervorst and M.A. Rookus and C. Seynaeve and J.G. Wijnen and {van Vreeswijk}, M. and M.J.L. Ligtenberg and {van der Luijt}, R. and J.J.P. Gille and M.M. Blok and C. Issacs and M.K. Humphreys and L. McGuffog and S. Healey and O.M. Sinilnikova and A.C. Antoniou and D. Easton and G. Chenevix-Trench",

year = "2009",

doi = "https://doi.org/10.1007/s10549-008-0257-1",

language = "English",

volume = "117",

pages = "371--379",

journal = "Breast cancer research and treatment",

issn = "0167-6806",

publisher = "Springer New York",

number = "2",

}

AUTHOR GROUP, Aittomaki, K, Hodgson, SV, Hogervorst, FB, Rookus, MA, Seynaeve, C, Wijnen, JG, van Vreeswijk, M, Ligtenberg, MJL, van der Luijt, R, Gille, JJP, Blok, MM, Issacs, C, Humphreys, MK, McGuffog, L, Healey, S, Sinilnikova, OM, Antoniou, AC, Easton, D & Chenevix-Trench, G 2009, 'No evidence that GATA3 rs570613 SNP modifies breast cancer risk', Breast cancer research and treatment, vol. 117, no. 2, pp. 371-379. https://doi.org/10.1007/s10549-008-0257-1

TY - JOUR

T1 - No evidence that GATA3 rs570613 SNP modifies breast cancer risk

AU - Johnatty, Sharon E.

AU - Couch, Fergus J.

AU - Fredericksen, Zachary

AU - Tarrell, Robert

AU - Spurdle, Amanda B.

AU - Beesley, Jonathan

AU - Chen, Xiaoqing

AU - Gschwantler-Kaulich, Daphne

AU - Singer, Christian F.

AU - Fuerhauser, Christine

AU - Fink-Retter, Anneliese

AU - Domchek, Susan M.

AU - Nathanson, Katherine L.

AU - Pankratz, Vernon S.

AU - Lindor, Noralane M.

AU - Godwin, Andrew K.

AU - Caligo, Maria A.

AU - Hopper, John

AU - Southey, Melissa C.

AU - Giles, Graham G.

AU - Justenhoven, Christina

AU - Brauch, Hiltrud

AU - Hamann, Ute

AU - Ko, Yon-Dschun

AU - Heikkinen, Tuomas

AU - Aaltonen, Kirsimari

AU - Aittomäki, Kristiina

AU - Blomqvist, Carl

AU - Nevanlinna, Heli

AU - Hall, Per

AU - Czene, Kamila

AU - Liu, Jianjun

AU - Peock, Susan

AU - Cook, Margaret

AU - Platte, Radka

AU - Gareth Evans, D.

AU - Lalloo, Fiona

AU - Eeles, Rosalind

AU - Pichert, Gabriella

AU - Eccles, Diana

AU - Davidson, Rosemarie

AU - Cole, Trevor

AU - Cook, Jackie

AU - Douglas, Fiona

AU - Chu, Carol

AU - Hodgson, Shirley

AU - Paterson, Joan

AU - van Os, Theo A. M.

AU - AUTHOR GROUP

AU - Aalfs, Cora

AU - Meijers-Heijboer, Hanne

AU - Aittomaki, K.

AU - Hodgson, SV

AU - Hogervorst, FB

AU - Rookus, M.A.

AU - Seynaeve, C.

AU - Wijnen, J.G.

AU - van Vreeswijk, M.

AU - Ligtenberg, M.J.L.

AU - van der Luijt, R.

AU - Gille, J.J.P.

AU - Blok, M.M.

AU - Issacs, C.

AU - Humphreys, M.K.

AU - McGuffog, L.

AU - Healey, S.

AU - Sinilnikova, O.M.

AU - Antoniou, A.C.

AU - Easton, D.

AU - Chenevix-Trench, G.

PY - 2009

Y1 - 2009

N2 - GATA-binding protein 3 (GATA3) is a transcription factor that is crucial to mammary gland morphogenesis and differentiation of progenitor cells, and has been suggested to have a tumor suppressor function. The rs570613 single nucleotide polymorphism (SNP) in intron 4 of GATA3 was previously found to be associated with a reduction in breast cancer risk in the Cancer Genetic Markers of Susceptibility project and in pooled analysis of two case-control studies from Norway and Poland (P (trend) = 0.004), with some evidence for a stronger association with estrogen receptor (ER) negative tumours [Garcia-Closas M et al. (2007) Cancer Epidemiol Biomarkers Prev 16:2269-2275]. We genotyped GATA3 rs570613 in 6,388 cases and 4,995 controls from the Breast Cancer Association Consortium (BCAC) and 5,617 BRCA1 and BRCA2 carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). We found no association between this SNP and breast cancer risk in BCAC cases overall (OR(per-allele) = 1.00, 95% CI 0.94-1.05), in ER negative BCAC cases (OR(per-allele) = 1.02, 95% CI 0.91-1.13), in BRCA1 mutation carriers RR(per-allele) = 0.99, 95% CI 0.90-1.09) or BRCA2 mutation carriers (RR(per-allele) = 0.93, 95% CI 0.80-1.07). We conclude that there is no evidence that either GATA3 rs570613, or any variant in strong linkage disequilibrium with it, is associated with breast cancer risk in women

AB - GATA-binding protein 3 (GATA3) is a transcription factor that is crucial to mammary gland morphogenesis and differentiation of progenitor cells, and has been suggested to have a tumor suppressor function. The rs570613 single nucleotide polymorphism (SNP) in intron 4 of GATA3 was previously found to be associated with a reduction in breast cancer risk in the Cancer Genetic Markers of Susceptibility project and in pooled analysis of two case-control studies from Norway and Poland (P (trend) = 0.004), with some evidence for a stronger association with estrogen receptor (ER) negative tumours [Garcia-Closas M et al. (2007) Cancer Epidemiol Biomarkers Prev 16:2269-2275]. We genotyped GATA3 rs570613 in 6,388 cases and 4,995 controls from the Breast Cancer Association Consortium (BCAC) and 5,617 BRCA1 and BRCA2 carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). We found no association between this SNP and breast cancer risk in BCAC cases overall (OR(per-allele) = 1.00, 95% CI 0.94-1.05), in ER negative BCAC cases (OR(per-allele) = 1.02, 95% CI 0.91-1.13), in BRCA1 mutation carriers RR(per-allele) = 0.99, 95% CI 0.90-1.09) or BRCA2 mutation carriers (RR(per-allele) = 0.93, 95% CI 0.80-1.07). We conclude that there is no evidence that either GATA3 rs570613, or any variant in strong linkage disequilibrium with it, is associated with breast cancer risk in women

U2 - https://doi.org/10.1007/s10549-008-0257-1

DO - https://doi.org/10.1007/s10549-008-0257-1

M3 - Article

C2 - 19082709

SN - 0167-6806

VL - 117

SP - 371

EP - 379

JO - Breast cancer research and treatment

JF - Breast cancer research and treatment

IS - 2

ER -